Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample sizeCOVID-19 치료에서 토실리주맙과 파비피라비르 병용: 소규모 표본 크기의 다기관 시험Randomized Controlled Trial Published on 2021-01-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] SARS, 임상, 진단, 치료법, 치료제, [키워드] 95 % CI Absorption addition assigned Blood routine clinical symptom Clinical symptoms Combination Combined therapy COVID-19 COVID-19 patient COVID-19 patients cumulative Deterioration drug Efficacy and safety elevated Favipiravir help IL-6 IMPROVE indicated inhibit interleukin interleukin-6 lung Lung CT Lung inflammation lung lesion Multicenter trial no significant difference Patient patients with COVID-19 Primary outcome pulmonary inflammation Randomly reported SARS-CoV-2 Serious Adverse Event Serious Adverse Events significant difference significantly significantly higher small sample size spread to the disease theory Tocilizumab Treatment treatment of COVID-19 with COVID-19 [DOI] 10.1016/j.biopha.2020.110825 PMC 바로가기 [Article Type] Randomized Controlled Trial
Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study중증 COVID-19 환자를 위한 Tocilizumab: 후향적, 다기관 연구Multicenter Study Published on 2021-01-012022-09-12 Journal: Expert review of anti-infective therapy [Category] MERS, 진단, [키워드] 24 hour age C-reactive protein change changes in clinical clinical status Concentration COVID-19 decrease dose Evidence fibrinogen Final IMPROVE inflammatory markers Inflammatory response inhibitor interleukin-6 interleukin-6 receptor male Oxygen therapy Patient patients patients died Poland procalcitonin reducing retrospective Retrospective study SARS-CoV-2 serum Seven severe coronavirus disease severe COVID-19 significantly Symptom symptom onset therapy Tocilizumab [DOI] 10.1080/14787210.2020.1800453 PMC 바로가기 [Article Type] Multicenter Study
Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series토실리주맙으로 치료받은 COVID-19 비만 환자의 과염증: 성공적인 사례 시리즈Case Reports Published on 2021-01-012022-09-12 Journal: Journal of investigative medicine high impact case [Category] 진단, [키워드] acute respiratory syndrome adjusted Administered Case report case sery Complication coronavirus COVID-19 COVID-19 disease COVID-19 obese patients Critical Critical care Cytokine storm syndrome discharged disease dose drug effective exclusion feasible highlight hospital hyperinflammation hyperinflammatory state Immunosuppression improvement Infection infections interleukin-6 intubation limit maximal dose mechanism obese patient obese patients obesity Oxygenation pathophysiology Patient regimen SARS-CoV-2 Sery shown suggested the timing Tocilizumab tocilizumab administration tomography treat Treatment worsening hypoxemia [DOI] 10.1177/23247096211037442 PMC 바로가기 [Article Type] Case Reports
High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDShUCMSC에서 IL-6 분비의 높은 유도는 COVID-19 관련 ARDS에 대한 치료법으로서 hUCMSC 및 TCZ의 잠재력을 최적화합니다Article Published on 2021-01-012022-09-12 Journal: Cell transplantation [Category] 진단, [키워드] acute respiratory distress analyzed anti-inflammatory effect ARDS Biological Blood Cell cellular Concentration correlation COVID-19 cytokine secretion ELISA evaluated Exogenous expression functional hUCMSC Hyperinflammatory syndrome IL-6 IL-6 level IL-6 levels IL-6 neutralizing antibody IL-6 receptor IL-6R induction Inflammation inhibited inhibitory effect interleukin-6 less Microarray mononuclear cell mRNA expression MTT Neutralizing neutralizing antibody PBMC PBMCs peripheral Potential proliferation reached reported Respiratory failure Responder Severe COVID-19 pneumonia supernatant syndrome TCZ therapeutic potential therapy Tocilizumab treat umbilical was measured was used [DOI] 10.1177/09636897211054481 PMC 바로가기 [Article Type] Article
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients염증 마커 miR-146a의 감소된 혈청 수준은 COVID-19 환자에서 토실리주맙에 대한 임상적 무반응과 관련이 있습니다Clinical Trial Published on 2021-01-012022-09-11 Journal: Mechanisms of ageing and development [Category] MERS, SARS, 바이오마커, 임상, 진단, [키워드] accounted adverse outcome affected age anti-IL-6 receptor biologic Biomarker Clinical course clinical response clinical trial COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients COVID-19 severity current death Decreased develop Digital disease droplet enrolled examined Health Healthcare systems healthy control inflammaging interleukin-6 interstitial pneumonia intravenous intravenous infusion lowest marker microRNA MicroRNAs miR-126 miR-146 miR-146a-5p miR-21 molecular non-responders Patient PCR quantified regulate respond responders RT-PCR Serum level serum levels serum sample serum samples subjects syndrome TCZ Tocilizumab Treatment [DOI] 10.1016/j.mad.2020.111413 PMC 바로가기 [Article Type] Clinical Trial
Feasibility of tocilizumab in ICU patients with COVID-19COVID-19가 있는 중환자실 환자에서 토실리주맙의 가능성Comment Published on 2021-01-012022-09-12 Journal: Journal of medical virology [Category] 진단, [키워드] ICU patient Tocilizumab with COVID-19 [DOI] 10.1002/jmv.26110 PMC 바로가기 [Article Type] Comment
Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report혈구포식성 림프조직구증가증 및 코로나19 환자를 위한 헬멧 마스크 및 토실리주맙: 증례 보고Case Reports Published on 2021-01-012022-09-12 Journal: Brazilian journal of anesthesiology (Elsevier) [Category] MERS, 진단, 치료제, [키워드] administration antiviral drug antiviral drugs Case report COVID-19 COVID-19 patient CRP D-dimer fatigue ferritin Fever H-scores Helmet mask Hemophagocytic lymphohistiocytosis (HLH) hemophagocytic lymphohistiocytosis syndrome hypoxemic IL-6 Improvements infused intensive care unit interleukin-6 intravenous intravenously Laboratory management Noninvasive ventilation Patient problems Respiratory failure severe COVID-19 Shortness of breath the patient Tocilizumab treat Triglyceride [DOI] 10.1016/j.bjane.2020.10.009 PMC 바로가기 [Article Type] Case Reports
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical TrialCOVID-19 및 중등도 또는 중증 폐렴으로 입원한 성인에서 Tocilizumab 대 일반 치료의 효과: 무작위 임상 시험Randomized Controlled Trial Published on 2021-01-012022-09-11 Journal: JAMA Internal Medicine [Category] 임상, 진단, 치료제, [키워드] 95% CI adjusted Admission adverse event adverse events age Analysis antibiotic Anticoagulants Antiviral agents ARD assigned Bayesian C-reactive protein Care clinical clinical status clinical trial clinically conducted Consent coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 pneumonia credible interval CrI death determine did not reduce died discharge Effect Efficacy elevated Factor Fewer patients Follow-up France greater hazard ratio Health Organization hyperinflammation Identifier IMPROVE indicated intensive care intensive care unit intention-to-treat basis interleukin-6 interquartile range intravenously investigator-initiated less mechanical ventilation median moderate moderate-to-severe COVID-19 pneumonia Mortality multicenter multiplicity NIV no difference Noninvasive ventilation occurred Open-label outcome overall survival oxygen oxygen supply oxygen support Patient patients patients hospitalized patients with COVID-19 performed Pneumonia posterior probability Primary outcomes randomized clinical trial Randomly receive recruited reduced risk risk difference scale secondary Secondary outcomes Serious Adverse Events severe pneumonia survival TCZ threshold Tocilizumab treat university hospital usual care usual care alone vasopressor support Ventilation WHO-CPS women World Health Organization [DOI] 10.1001/jamainternmed.2020.6820 PMC 바로가기 [Article Type] Randomized Controlled Trial
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective studyResearch article Published on 2021-01-012022-10-05 Journal: Journal of autoimmunity [Category] SARS, 신약개발, [키워드] age Analysis biological drug biologics CFR co-morbidity conditions COVID COVID 19 COVID-19 COVID-19 pandemic determine diagnosed with COVID-19 disease DMARDs drug evaluated fatality Final General population Hydroxychloroquine Immunocompromised Immunosuppressant Immunosuppressive treatment increased risk Infection infection rate infections Italian region Local lombardy management Marche mortality rate multicentre negative swab no difference objective Patient patients from Lombardy question raised receiving registries registry data Result Retrospective study rheumatic disease risk risk factor Seven small molecule Small molecules susceptibility susceptible Symptom telephone contact the disease the patient Tocilizumab treat treated Treatment with COVID-19 [DOI] 10.1016/j.jaut.2020.102545 [Article Type] Research article
Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2중증 급성 호흡기 증후군 코로나바이러스 2와 관련된 소아의 다기관 염증 증후군에서 토실리주맙 사용Comment Published on 2021-01-012022-09-12 Journal: The Journal of pediatrics [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome children coronavirus Inflammatory syndrome Tocilizumab [DOI] 10.1016/j.jpeds.2020.09.054 PMC 바로가기 [Article Type] Comment